129 related articles for article (PubMed ID: 19004723)
1. [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Laurent-Puig P; Lièvre A; Ducreux M; Loriot MA
Bull Cancer; 2008 Oct; 95(10):935-42. PubMed ID: 19004723
[TBL] [Abstract][Full Text] [Related]
2. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
3. [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Ducreux M; Boige V; Malka D; Laurent-Puig P
Bull Cancer; 2008 Oct; 95(10):931-4. PubMed ID: 19004722
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Tan BR; McLeod HL
Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
[TBL] [Abstract][Full Text] [Related]
5. Tailoring chemotherapy in advanced colorectal cancer.
Park DJ; Stoehlmacher J; Lenz HJ
Curr Opin Pharmacol; 2003 Aug; 3(4):378-85. PubMed ID: 12901946
[TBL] [Abstract][Full Text] [Related]
6. Cancer pharmacogenomics: current and future applications.
Watters JW; McLeod HL
Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
[TBL] [Abstract][Full Text] [Related]
7. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
Grem JL
Semin Oncol; 2005 Feb; 32(1):120-7. PubMed ID: 15726514
[TBL] [Abstract][Full Text] [Related]
9. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
10. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
11. Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
Isaakidou A; Gazouli M; Aravantinos G; Pectasides D; Theodoropoulos GE
J Cancer Res Ther; 2016; 12(1):193-7. PubMed ID: 27072236
[TBL] [Abstract][Full Text] [Related]
12. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
13. [Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Astier A
Ann Pharm Fr; 2010 Jul; 68(4):233-53. PubMed ID: 20637356
[TBL] [Abstract][Full Text] [Related]
14. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Bhushan S; McLeod H; Walko CM
Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
[TBL] [Abstract][Full Text] [Related]
16. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
Kleist B; Kempa M; Meurer T; Poetsch M
J Clin Pathol; 2016 Mar; 69(3):204-8. PubMed ID: 26281864
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
18. [Role of pharmacogenetics in chemotherapy of colorectal cancers].
Ceppa F; Fontan E; Cremades S; Bihannic R; Bousquet A; Beauvillain L; Burnat P
Rev Med Interne; 2007 Sep; 28(9):594-602. PubMed ID: 17624636
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Baynes RD; Gansert J
Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
[TBL] [Abstract][Full Text] [Related]
20. Determinants of chemosensitivity in gastric cancer.
Park DJ; Lenz HJ
Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]